Since its inception in 1985, Gemini Bio’s focus and niche has
always been to produce consistent, high quality products, coupled
with exceptional, personalized service. The company began
operations in Calabasas, California, with marketing activities
targeting the research and biotech community across the state. As
a result of continued and progressive success, Gemini
consistently expanded the sales force to be able to service the
entire United States. After undergoing multiple expansions,
Gemini now operates out of a 12,000 square foot manufacturing
facility in West Sacramento, California.
Today, Gemini is a leading manufacturer and supplier of cell
culture media, sera, and other reagents to the scientific
community across academic research and the biotechnology, cell
and gene therapy, and biopharma industries. A national sales
force and an international distribution network serves cell
culture laboratories worldwide.
In September 2018, BelHealth Investment Partners, a healthcare
private equity firm, invested in Gemini Bio. A new leadership team led by CEO Dale Gordon was
brought on to guide the company through its exciting next
chapter. With this growth investment, Gemini has plans to move
into a new state-of-the-art 25,000 square foot facility in West
Sacramento by early 2020.
Throughout its growth, Gemini has maintained the personalized
service on which its reputation was built. Samples and orders are
often processed and shipped the same day they are requested,
enabling customers to receive their orders the very next day.
Gemini’s sales team visits customers regularly to provide
mutually agreed solutions to customer needs. Today, we are proud
of what we uniquely offer at Gemini: competitively priced
products, extensively tested and proven to be of high quality
over the last 34 years, combined with exceedingly unbeatable
service within the industry.